William Seth Stone, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychotic Disorders | 51 | 2024 | 3028 | 4.460 |
Why?
|
| Schizophrenia | 82 | 2024 | 6867 | 3.740 |
Why?
|
| Schizophrenic Psychology | 33 | 2020 | 1677 | 2.110 |
Why?
|
| Endophenotypes | 23 | 2023 | 250 | 1.830 |
Why?
|
| Schizotypal Personality Disorder | 7 | 2012 | 288 | 1.090 |
Why?
|
| Neuropsychological Tests | 41 | 2021 | 6963 | 0.880 |
Why?
|
| Social Adjustment | 4 | 2021 | 632 | 0.820 |
Why?
|
| Cognition | 15 | 2024 | 6686 | 0.780 |
Why?
|
| Multilingualism | 1 | 2021 | 87 | 0.770 |
Why?
|
| China | 13 | 2020 | 2223 | 0.740 |
Why?
|
| Antipsychotic Agents | 10 | 2022 | 3055 | 0.740 |
Why?
|
| Memory, Short-Term | 9 | 2020 | 973 | 0.730 |
Why?
|
| Verbal Learning | 7 | 2022 | 466 | 0.730 |
Why?
|
| Family | 16 | 2016 | 3141 | 0.670 |
Why?
|
| Memory Disorders | 6 | 2013 | 1180 | 0.630 |
Why?
|
| Cognition Disorders | 17 | 2023 | 4026 | 0.580 |
Why?
|
| Psychiatric Status Rating Scales | 19 | 2020 | 6028 | 0.490 |
Why?
|
| Disease Progression | 12 | 2022 | 13237 | 0.480 |
Why?
|
| Psychological Tests | 1 | 2016 | 649 | 0.460 |
Why?
|
| Siblings | 6 | 2015 | 853 | 0.450 |
Why?
|
| Affective Disorders, Psychotic | 3 | 2021 | 191 | 0.410 |
Why?
|
| Risperidone | 2 | 2012 | 383 | 0.380 |
Why?
|
| Adolescent | 63 | 2023 | 85409 | 0.380 |
Why?
|
| Longitudinal Studies | 21 | 2024 | 13880 | 0.360 |
Why?
|
| Young Adult | 46 | 2023 | 56252 | 0.340 |
Why?
|
| Glucose | 6 | 2014 | 4376 | 0.330 |
Why?
|
| Humans | 128 | 2024 | 739219 | 0.300 |
Why?
|
| Memory | 7 | 2021 | 2161 | 0.300 |
Why?
|
| Verbal Behavior | 2 | 2007 | 339 | 0.290 |
Why?
|
| Hippocampus | 2 | 2011 | 3656 | 0.290 |
Why?
|
| Auditory Perception | 3 | 2016 | 567 | 0.280 |
Why?
|
| Tobacco Use Disorder | 1 | 2012 | 682 | 0.280 |
Why?
|
| Adult | 68 | 2023 | 213375 | 0.270 |
Why?
|
| Genetic Predisposition to Disease | 22 | 2015 | 17384 | 0.270 |
Why?
|
| Neural Inhibition | 3 | 2017 | 595 | 0.270 |
Why?
|
| Saccades | 3 | 2014 | 247 | 0.250 |
Why?
|
| Acoustic Stimulation | 7 | 2020 | 1216 | 0.250 |
Why?
|
| Mental Recall | 7 | 2014 | 1201 | 0.250 |
Why?
|
| Male | 74 | 2023 | 348967 | 0.250 |
Why?
|
| Nerve Net | 3 | 2021 | 2175 | 0.240 |
Why?
|
| Evoked Potentials, Auditory | 3 | 2014 | 525 | 0.240 |
Why?
|
| Glucose Solution, Hypertonic | 1 | 2003 | 10 | 0.240 |
Why?
|
| Cholinergic Antagonists | 2 | 2023 | 162 | 0.240 |
Why?
|
| Case-Control Studies | 15 | 2020 | 21691 | 0.230 |
Why?
|
| Event-Related Potentials, P300 | 2 | 2014 | 150 | 0.230 |
Why?
|
| Syndrome | 4 | 2020 | 3241 | 0.230 |
Why?
|
| Attention | 8 | 2021 | 2400 | 0.220 |
Why?
|
| North America | 6 | 2022 | 1249 | 0.220 |
Why?
|
| Narcolepsy | 2 | 2016 | 195 | 0.220 |
Why?
|
| Delusions | 2 | 2022 | 300 | 0.220 |
Why?
|
| Brain | 15 | 2022 | 26293 | 0.220 |
Why?
|
| Enzymes | 1 | 2004 | 267 | 0.220 |
Why?
|
| Theory of Mind | 1 | 2024 | 83 | 0.210 |
Why?
|
| Female | 74 | 2023 | 378808 | 0.210 |
Why?
|
| Language | 2 | 2021 | 1447 | 0.210 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2022 | 33 | 0.210 |
Why?
|
| Cerebellar Nuclei | 1 | 2021 | 56 | 0.200 |
Why?
|
| Smoking | 5 | 2015 | 8959 | 0.190 |
Why?
|
| Temporal Lobe | 3 | 2007 | 1670 | 0.190 |
Why?
|
| Family Therapy | 1 | 2021 | 207 | 0.180 |
Why?
|
| Glycolysis | 1 | 2004 | 825 | 0.180 |
Why?
|
| Clozapine | 1 | 2003 | 498 | 0.180 |
Why?
|
| Psychometrics | 5 | 2020 | 2995 | 0.180 |
Why?
|
| Risk | 9 | 2022 | 9684 | 0.170 |
Why?
|
| Hallucinations | 1 | 2022 | 359 | 0.170 |
Why?
|
| Time Factors | 2 | 2020 | 40040 | 0.170 |
Why?
|
| Middle Aged | 41 | 2021 | 212833 | 0.160 |
Why?
|
| Prefrontal Cortex | 2 | 2007 | 2137 | 0.160 |
Why?
|
| Social Behavior Disorders | 2 | 2017 | 97 | 0.160 |
Why?
|
| Reference Values | 6 | 2016 | 4981 | 0.150 |
Why?
|
| Cluster Analysis | 4 | 2012 | 2710 | 0.150 |
Why?
|
| Auditory Perceptual Disorders | 1 | 2017 | 36 | 0.150 |
Why?
|
| Environment | 5 | 2013 | 1110 | 0.140 |
Why?
|
| Independent Living | 1 | 2020 | 559 | 0.140 |
Why?
|
| Remission Induction | 1 | 2022 | 2378 | 0.140 |
Why?
|
| Phenotype | 8 | 2010 | 16300 | 0.140 |
Why?
|
| Cannabis | 1 | 2022 | 430 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2020 | 2731 | 0.130 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2020 | 702 | 0.130 |
Why?
|
| Minority Groups | 1 | 2023 | 1197 | 0.130 |
Why?
|
| Task Performance and Analysis | 2 | 2017 | 780 | 0.130 |
Why?
|
| Basal Metabolism | 1 | 2016 | 168 | 0.130 |
Why?
|
| Risk Factors | 20 | 2023 | 71972 | 0.130 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2017 | 230 | 0.130 |
Why?
|
| Epidemiologic Research Design | 2 | 2015 | 368 | 0.120 |
Why?
|
| Analysis of Variance | 6 | 2017 | 6364 | 0.120 |
Why?
|
| Paternal Age | 1 | 2014 | 84 | 0.120 |
Why?
|
| Sensory Gating | 1 | 2014 | 47 | 0.120 |
Why?
|
| Depression | 2 | 2020 | 7689 | 0.120 |
Why?
|
| Speech Perception | 2 | 2014 | 487 | 0.110 |
Why?
|
| Sex Differentiation | 1 | 2013 | 73 | 0.110 |
Why?
|
| Peer Group | 1 | 2017 | 635 | 0.110 |
Why?
|
| Models, Psychological | 1 | 2017 | 809 | 0.110 |
Why?
|
| Internal-External Control | 1 | 2014 | 362 | 0.110 |
Why?
|
| Genetics, Behavioral | 1 | 2012 | 53 | 0.110 |
Why?
|
| Hydrocortisone | 1 | 2020 | 1810 | 0.100 |
Why?
|
| Child | 12 | 2023 | 77029 | 0.100 |
Why?
|
| Schizoid Personality Disorder | 1 | 2010 | 14 | 0.100 |
Why?
|
| California | 1 | 2014 | 1400 | 0.090 |
Why?
|
| Stress, Psychological | 2 | 2020 | 4214 | 0.090 |
Why?
|
| Rural Population | 1 | 2020 | 2181 | 0.090 |
Why?
|
| Cerebral Cortex | 4 | 2022 | 5717 | 0.090 |
Why?
|
| Interpersonal Relations | 1 | 2017 | 1421 | 0.090 |
Why?
|
| Evoked Potentials | 1 | 2015 | 1057 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2012 | 11985 | 0.090 |
Why?
|
| Cohort Studies | 6 | 2021 | 40385 | 0.090 |
Why?
|
| Pilot Projects | 6 | 2017 | 8272 | 0.090 |
Why?
|
| Emotions | 2 | 2012 | 2642 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2022 | 2091 | 0.090 |
Why?
|
| Cooperative Behavior | 2 | 2006 | 1501 | 0.090 |
Why?
|
| Lod Score | 2 | 2013 | 615 | 0.080 |
Why?
|
| Nuclear Family | 2 | 2014 | 318 | 0.080 |
Why?
|
| Psychomotor Performance | 2 | 2014 | 1898 | 0.080 |
Why?
|
| Wechsler Scales | 2 | 2013 | 259 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2005 | 2028 | 0.080 |
Why?
|
| Cholecalciferol | 1 | 2013 | 534 | 0.080 |
Why?
|
| Family Health | 2 | 2012 | 1281 | 0.080 |
Why?
|
| Self Concept | 1 | 2014 | 1024 | 0.080 |
Why?
|
| Substance-Related Disorders | 2 | 2022 | 4239 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2019 | 12177 | 0.080 |
Why?
|
| Depressive Disorder, Major | 2 | 2020 | 4604 | 0.080 |
Why?
|
| Developing Countries | 1 | 2020 | 2779 | 0.080 |
Why?
|
| Age Factors | 4 | 2023 | 18347 | 0.080 |
Why?
|
| Genotype | 5 | 2013 | 12950 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2013 | 1143 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2023 | 35274 | 0.070 |
Why?
|
| Risk Assessment | 4 | 2022 | 23292 | 0.070 |
Why?
|
| Aged | 19 | 2021 | 162667 | 0.070 |
Why?
|
| Sex Factors | 3 | 2020 | 10397 | 0.070 |
Why?
|
| Disease Susceptibility | 3 | 2021 | 1778 | 0.070 |
Why?
|
| Mental Processes | 1 | 2007 | 249 | 0.070 |
Why?
|
| Body Weight | 1 | 2016 | 4659 | 0.070 |
Why?
|
| Inheritance Patterns | 1 | 2007 | 339 | 0.070 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2021 | 3635 | 0.070 |
Why?
|
| Social Behavior | 1 | 2012 | 1131 | 0.060 |
Why?
|
| Psychology | 1 | 2007 | 351 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2006 | 1583 | 0.060 |
Why?
|
| Chromosome Mapping | 3 | 2004 | 4744 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2012 | 4268 | 0.060 |
Why?
|
| Phosphofructokinase-1 | 1 | 2004 | 52 | 0.060 |
Why?
|
| Pedigree | 4 | 2007 | 4641 | 0.060 |
Why?
|
| Phosphofructokinase-2 | 1 | 2004 | 32 | 0.060 |
Why?
|
| Saccharin | 1 | 2003 | 20 | 0.060 |
Why?
|
| Hexokinase | 1 | 2004 | 126 | 0.060 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 1327 | 0.060 |
Why?
|
| Telemedicine | 1 | 2021 | 2844 | 0.060 |
Why?
|
| Terminology as Topic | 2 | 2001 | 1548 | 0.060 |
Why?
|
| Cerebellum | 1 | 2010 | 1513 | 0.060 |
Why?
|
| Genetic Linkage | 3 | 2004 | 2433 | 0.060 |
Why?
|
| Association Learning | 1 | 2005 | 224 | 0.060 |
Why?
|
| Aging | 1 | 2022 | 8607 | 0.060 |
Why?
|
| Severity of Illness Index | 6 | 2015 | 15510 | 0.050 |
Why?
|
| Intelligence Tests | 1 | 2024 | 505 | 0.050 |
Why?
|
| Linear Models | 3 | 2020 | 5946 | 0.050 |
Why?
|
| Pyruvate Kinase | 1 | 2004 | 189 | 0.050 |
Why?
|
| Anesthesiology | 1 | 2012 | 1043 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2014 | 5050 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2011 | 2693 | 0.050 |
Why?
|
| Social Participation | 1 | 2023 | 171 | 0.050 |
Why?
|
| Social Environment | 1 | 2006 | 1014 | 0.050 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2010 | 1424 | 0.050 |
Why?
|
| Electroencephalography | 5 | 2015 | 6133 | 0.050 |
Why?
|
| Dietary Supplements | 1 | 2013 | 3279 | 0.050 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 2023 | 0.050 |
Why?
|
| Neuregulins | 1 | 2019 | 35 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2006 | 2630 | 0.050 |
Why?
|
| Mood Disorders | 1 | 2006 | 1102 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 2010 | 2564 | 0.040 |
Why?
|
| Acoustics | 1 | 2020 | 239 | 0.040 |
Why?
|
| Technology | 1 | 2021 | 299 | 0.040 |
Why?
|
| Models, Genetic | 2 | 2006 | 3495 | 0.040 |
Why?
|
| Prognosis | 4 | 2022 | 28901 | 0.040 |
Why?
|
| Personality Inventory | 2 | 2012 | 1026 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2005 | 2032 | 0.040 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1998 | 104 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 15035 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2005 | 2291 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 12235 | 0.040 |
Why?
|
| Arousal | 2 | 2015 | 1164 | 0.040 |
Why?
|
| Comorbidity | 1 | 2012 | 10362 | 0.040 |
Why?
|
| Behavioral Symptoms | 1 | 1999 | 174 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 594 | 0.040 |
Why?
|
| Contingent Negative Variation | 1 | 2017 | 34 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2021 | 38941 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2005 | 3909 | 0.040 |
Why?
|
| Potassium Channels | 1 | 2019 | 561 | 0.040 |
Why?
|
| Corpus Callosum | 1 | 2021 | 738 | 0.040 |
Why?
|
| Calorimetry, Indirect | 1 | 2016 | 182 | 0.030 |
Why?
|
| Saliva | 1 | 2020 | 805 | 0.030 |
Why?
|
| Blood-Brain Barrier | 1 | 2022 | 1013 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 9393 | 0.030 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2017 | 274 | 0.030 |
Why?
|
| Eye Movement Measurements | 1 | 2014 | 35 | 0.030 |
Why?
|
| Prevalence | 1 | 2012 | 15152 | 0.030 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 24711 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 7897 | 0.030 |
Why?
|
| CpG Islands | 2 | 2012 | 1163 | 0.030 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 1998 | 402 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14721 | 0.030 |
Why?
|
| Patient Selection | 1 | 2006 | 4211 | 0.030 |
Why?
|
| Social Stigma | 1 | 2020 | 695 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2020 | 1951 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 1175 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2023 | 53036 | 0.030 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2016 | 270 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 6478 | 0.030 |
Why?
|
| Water | 1 | 2019 | 1376 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 19787 | 0.030 |
Why?
|
| Computers | 1 | 2015 | 614 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 2015 | 975 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2002 | 1621 | 0.030 |
Why?
|
| Hand Strength | 1 | 2014 | 441 | 0.020 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 7726 | 0.020 |
Why?
|
| Down Syndrome | 1 | 1998 | 873 | 0.020 |
Why?
|
| Genetic Pleiotropy | 1 | 2011 | 182 | 0.020 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 460 | 0.020 |
Why?
|
| Reaction Time | 2 | 2006 | 2097 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2002 | 12945 | 0.020 |
Why?
|
| Neck Pain | 1 | 2010 | 179 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2017 | 1824 | 0.020 |
Why?
|
| Happiness | 1 | 2010 | 170 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2005 | 6661 | 0.020 |
Why?
|
| Theta Rhythm | 1 | 2010 | 210 | 0.020 |
Why?
|
| Epistasis, Genetic | 1 | 2011 | 365 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2024 | 7689 | 0.020 |
Why?
|
| United States | 3 | 2012 | 69568 | 0.020 |
Why?
|
| Serial Learning | 1 | 2008 | 45 | 0.020 |
Why?
|
| ROC Curve | 1 | 2016 | 3524 | 0.020 |
Why?
|
| Mental Disorders | 2 | 2006 | 6570 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2011 | 491 | 0.020 |
Why?
|
| Fasting | 1 | 2014 | 1587 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 717 | 0.020 |
Why?
|
| Communication | 1 | 2021 | 3723 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2019 | 3605 | 0.020 |
Why?
|
| Massachusetts | 2 | 2013 | 8668 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2016 | 12655 | 0.020 |
Why?
|
| Age of Onset | 1 | 2014 | 3263 | 0.020 |
Why?
|
| Body Composition | 1 | 2016 | 2396 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 844 | 0.020 |
Why?
|
| Visual Perception | 1 | 2015 | 1418 | 0.020 |
Why?
|
| Weight Gain | 1 | 2016 | 2278 | 0.020 |
Why?
|
| Genetic Research | 1 | 2006 | 172 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 940 | 0.020 |
Why?
|
| Color Perception | 1 | 2006 | 213 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2021 | 40801 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 6451 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 1186 | 0.020 |
Why?
|
| Orientation | 1 | 2006 | 327 | 0.020 |
Why?
|
| Universities | 1 | 2010 | 946 | 0.020 |
Why?
|
| Psychotropic Drugs | 1 | 2010 | 891 | 0.020 |
Why?
|
| Leukocytes | 1 | 2012 | 2036 | 0.020 |
Why?
|
| Executive Function | 1 | 2013 | 1356 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2011 | 2533 | 0.010 |
Why?
|
| Blood Glucose | 2 | 2014 | 6236 | 0.010 |
Why?
|
| New York | 1 | 2006 | 888 | 0.010 |
Why?
|
| Anisotropy | 1 | 2007 | 1264 | 0.010 |
Why?
|
| Headache | 1 | 2010 | 1199 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 3922 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2013 | 15500 | 0.010 |
Why?
|
| Influenza, Human | 1 | 2014 | 1476 | 0.010 |
Why?
|
| Personality Disorders | 1 | 2006 | 708 | 0.010 |
Why?
|
| Overweight | 1 | 2013 | 2355 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2006 | 706 | 0.010 |
Why?
|
| Parents | 1 | 2015 | 3368 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 2410 | 0.010 |
Why?
|
| Artifacts | 1 | 2010 | 1896 | 0.010 |
Why?
|
| Histones | 1 | 2011 | 2592 | 0.010 |
Why?
|
| Twin Studies as Topic | 1 | 2001 | 105 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13400 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 5863 | 0.010 |
Why?
|
| Observer Variation | 1 | 2006 | 2587 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2015 | 9132 | 0.010 |
Why?
|
| Volition | 1 | 1999 | 63 | 0.010 |
Why?
|
| Diseases in Twins | 1 | 2001 | 449 | 0.010 |
Why?
|
| Obstetric Labor Complications | 1 | 2001 | 240 | 0.010 |
Why?
|
| Paired-Associate Learning | 1 | 1998 | 52 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2011 | 3441 | 0.010 |
Why?
|
| Consensus | 1 | 2007 | 2912 | 0.010 |
Why?
|
| Mental Status Schedule | 1 | 1998 | 321 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 3340 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2011 | 13006 | 0.010 |
Why?
|
| Neural Pathways | 1 | 2007 | 2971 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 4254 | 0.010 |
Why?
|
| Mutation | 2 | 2014 | 29659 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2010 | 8553 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2014 | 76632 | 0.010 |
Why?
|
| Obesity | 1 | 2016 | 12641 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2014 | 25470 | 0.010 |
Why?
|
| Infant | 1 | 2014 | 34923 | 0.010 |
Why?
|
| Psychiatry | 1 | 2004 | 1686 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 8919 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 15191 | 0.010 |
Why?
|
| Quality of Life | 1 | 2011 | 12640 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2010 | 62691 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2004 | 12064 | 0.000 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1998 | 10939 | 0.000 |
Why?
|
| Animals | 1 | 2012 | 168358 | 0.000 |
Why?
|
| Pregnancy | 1 | 2001 | 29003 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1998 | 57639 | 0.000 |
Why?
|